Schmerzmedizin 6 / 2017

Literatur 1. Rosen A et al. Global trends in testicular cancer incidence and mortality. Eur Urol 2011;60:374 2. Lip SZ et al. A meta-analysis of the risk of boys with isolated cryptorchidism develo- ping testicular cancer in later life. Arch Dis Child 2013; 98:20–6 3. Eisenberg ML et al. Increased Risk of Cancer in Infertile Men: Analysis of U.S. Claims Data. J Urol 2015;193(5):1596–601 4. Li N et al. Muscle-building supplement use and increased risk of testicular germ cell cancer in men from Connecticut and Massa- chusetts. Br J Cancer 2015;112(7):1247–50 5. Huang YHJ et al. An Epidemiologic Review of Marijuana and Cancer: An Update. Can- cer Epidemiol Biomarkers Prev 2015;24(1): 15–31 6. Brenner H et al. Long-term survival expec- tations of cancer patients in Europe in 2000-2002. Eur J Cancer, 2009;45(6):1028–41 7. Osmanska M, Borkowska A, Makarewicz R. Evaluation of quality of life, anxiety and de- pression in testicular cancer patients during chemotherapy and after anticancer treat- ment. Psychiatria Polska, 2009;44(4): 543–56 8. Dahl AA et al. Study of anxiety disorder and depression in long-term survivors of testi- cular cancer. J Clin Oncol 2005;23(10):2389– 95 9. Albers P et al. Guidelines on Testicular Can- cer: 2015 Update. European Urology 2015; 68:1054–68 10. Maio G. Der Schmerz als Widerfahrnis, S. 169-179, Maio G, Bozzaro C, Eichinger T (Hrsg.): Leid und Schmerz, Konzeptionelle Annäherungen und medizinethische Impli- kationen, Karl-Alber-Verlag, Freiburg/Mün- chen, 2015, ISBN 978-3-495-48738–9 11. Rutskij R et al. A study of coping in long- term testicular cancer survivors. Psychol Health Med 2010;15(2):146–58 12. Trevino KM et al. Coping and psychological distress in young adults with advanced can- cer. J Support Oncol 2012;10(3):124–30 13. Morton LM et al. Stomach cancer risk fol- lowing radiotherapy for testicular cancer. J Clin Oncol 2013,31:4536. 14. Hauptmann M et al. Increased stomach cancer risk following radiotherapy for testi- cular cancer. BJ Cancer 2015;112:44–51 15. Fung C et al. Solid Tumors After Chemothe- rapy or Surgery for Testicular Nonsemino- ma: A Population-Based Study. J Clin Oncol 2013,31:3807–14 16. Curreri SA, Fung C, Beard CJ. Secondary ma- lignant neoplasms in testicular cancer sur- vivors. Urol Oncol 2015;33:392–98 17. Hjelle LV, Gundersen OM, Oldenburg J et al. Long-term Platinum Retention After Plati- num-based Chemotherapy in Testicular Cancer Survivors: A 20-Year Follow-up Stu- dy. Anticancer Res 2015; 35:1619–26 18. Fung C, Fossa SD, Milano MT et al. Cardio­ vascular Disease Mortality After Chemothe- rapy or Surgery for Testicular Nonsemino- ma: A Population-Based Study. J Clin Oncol 2015;33:3105–15 19. Willemse PM et al. Prevalence of the meta- bolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. BJC 2013; 109:60–7 20. Alanee S, Russo P. Suicide in men with testis cancer. Eur J Cancer Care 2012; 21(6):817–21 21. Klaassen Z, Jen RP, DiBianco JM et al. Fac- tors Associated With Suicide in Patients With Genitourinary Malignancies. Cancer 2015;121(11):1864–72 22. Hoyt MA et al. Mechanisms of navigating goals after testicular cancer: Meaning and emotion regulation. Psychooncology, Jan 2016. ISSN 1099–1611 23. Robert Koch Institut. Bericht zum Krebsge- schehen in Deutschland 2016: Berlin. 24. Schmoll HJ, Höffken K, Possinger K (Hrsg).: Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer-Verlag, Heidelberg, 2009 25. Brennan, P et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 2000; 86(2):289–94 26. Brennan P et al. The contribution of cigaret- te smoking to bladder cancer in women (pooled European data). Cancer Causes Control 2001;12(5):411–7 27. Golka K, Kopps S, Myslak ZW. Carcinogenici- ty of azo colorants: influence of solubility and bioavailability. Toxicol Lett 2004; 151(1):203–10 28. Fortuny J et al. Use of analgesics and non­ steroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol Biomarkers Prev 2006;15(9):1696–1702 29. Fortuny J et al. Analgesic and anti-inflamm- atory drug use and risk of bladder cancer: a population based case control study. BMC Urol 2007;7:13 30. Kantor AF et al. Urinary tract infection and risk of bladder cancer. Am J Epidemiol 1984; 119(4):510–5 31. Owen HC et al. Low frequency of epigenetic events in urothelial tumors in young pati- ents. J Urol 2010;184(2):459–63 32. Fritsche, HM et al. Characteristics and out- comes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 2010;57(2):300–9 33. van den Bosch S, Witjes JA: Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systema- tic review. Eur Urol 2011;60(3):493-500 34. Matsumoto K et al. Risk of subsequent tu- mour recurrence and stage progression in bacille Calmette-Guerin relapsing non-mu- scle-invasive bladder cancer. BJU Int 2012; 110(11B): E508–E513 35. von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17): 3068–77 36. Sharma P et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial Lancet Oncol 2017;18(3):312– 322 37. Balar AV et al. First-line pembrolizumab in cisplatin-ineligible patients with locally ad- vanced and unresectable or metastatic uro- thelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017, Online 26. September, pii: S1470– 2045(17)30616–2 38. Sylvester RJ et al. Predicting recurrence and progression in individual patients with sta- ge Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 pati- ents from seven EORTC trials. Eur Urol 2006;49(3):466–5 39. Dossey L. Confronting Death Consciously: A Look at Terror Management Theory and Im- mortality Awareness Theory. Explore: The Journal of Science an Healing 2017;13(2): 81–7 40. Schulz C, Dunger C, Seidlein AH, Schallen- burger M, Piechkamp F, Schnell MW. Der unvermeidliche Zyklus des Lebens – Todes- vorstellungen professioneller Helfer in der Begleitung sterbender Menschen. Palliativ- medizin 2016;17(05):1-59 41. Smith LM, Kasser T. Mortality Salience Incre- ases Defensive Distancing From People With Terminal Cancer. Death Stud. 2014;38(1-5):44–53 42. Stiefel F et al. Collusions between patients and clinicians in end-of-life care: why clarity matters. J Pain Symptom Manage. 2017;53(4):776–82 43. Mead GM et al. The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for me- tastatic germ cell tumours. Clin Oncol (R Coll Radiol) 1997;9:207 44. Engel GL 1977. The need for a new model: a challenge for biomedicine. Science 196, pp.129–137 45. Gasser T. Basiswissen der Urologie. 6. Aufl. 2015 Springer, Berlin, Heidelberg Schmerzmedizin 2017; 33 (6) 33

RkJQdWJsaXNoZXIy MjQxNTg=